联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03933 联邦制药

休市中 11-13 16:08:17

7.485

-0.240

-3.11%

最高7.710	最低7.475	成交量184.60万
今开7.600	昨收7.725	日振幅3.04%
总市值147.45亿	流通市值147.45亿	总股本19.70亿
成交额1,394万	换手率0.09%	流通股本19.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"联邦制药","latestPrice":7.485,"timestamp":1794557297007,"preClose":7.725,"halted":0,"volume":1846000,"delay":0,"changeRate":-0.03106796116504846,"floatShares":1970000000,"shares":1970000000,"eps":1.1065,"marketStatus":"休市中","change":-0.24,"latestTime":"11-13 16:08:17","open":7.6,"high":7.71,"low":7.475,"amount":13935408,"amplitude":0.030421,"askPrice":7.485,"askSize":48000,"bidPrice":7.475,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":0.317137,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":7,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":7.725,"dividendRate":0.03996,"openAndCloseTimeList":[[1794533400000,1794542400000],[1794546000000,1794556800000]],"volumeRatio":0.5678188221016544,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933","defaultTab":"news","newsList":[{"id":"2683659904","title":"联邦制药(03933)：共约253.48万股奖励股份已获归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2683659904","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683659904?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:49","pubTimestamp":1794739790,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)公布，共约253.48万股奖励股份已根据2023年股份奖励计划的条款及2025年绩效目标的达标情况，于2026年11月13日归属于相关的承授人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683599026","title":"联邦制药(03933.HK)：共约253.48万股奖励股份已获归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2683599026","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683599026?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:49","pubTimestamp":1794739790,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B3M56506.USD","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171547570","title":"联邦制药(03933)披露2023年股份奖励计划首批归属 共计2,534,814股","url":"https://stock-news.laohu8.com/highlight/detail?id=1171547570","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171547570?lang=zh_cn&edition=full","pubTime":"2026-11-15 18:32","pubTimestamp":1794738738,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司11月13日发布自愿性公告，披露根据2023年股份奖励计划的条款及2025年绩效目标的达成情况，公司已于2026年11月13日向相关承授人归属合计2,534,814股奖励股份。董事会主席兼执行董事蔡海山获授153,360股。执行董事蔡绍哲获授71,680股。董事层合计获得381,840股。公司表示，本次股份归属旨在根据既定的2023年股份奖励计划激励和留任核心管理层及员工，以期进一步提升公司整体业绩表现。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152026990","title":"联邦制药10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1152026990","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152026990?lang=zh_cn&edition=full","pubTime":"2026-11-06 10:51","pubTimestamp":1793933495,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司于2026年11月6日公布截至2026年10月31日的股份变动月报表。根据公告，本月内公司股本及发行股份情况保持稳定，未有新增发行、购回或注销。联邦制药当前法定注册股本为38,000,000港元，面值每股0.01港元，对应授权股份总数3,800,000,000股。截至本月末，公司已发行股份总数为1,970,276,508股，库存股份为0股，均与上月保持一致。所有股份相关事项均已获董事会正式授权，并严格遵守香港联合交易所有限公司证券上市规则及适用法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015580","title":"港股异动 | 联邦制药(03933.HK)早盘涨超6% 司美格鲁肽注射液体重管理适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015580","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681015580?lang=zh_cn&edition=full","pubTime":"2026-11-05 10:36","pubTimestamp":1793846207,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B3M56506.USD","BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681090182","title":"联邦制药：司美格鲁肽注射液上市注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2681090182","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681090182?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:57","pubTimestamp":1793840220,"startTime":"0","endTime":"0","summary":"11月4日，联邦制药（03933）发布公告，本公司全资附属公司珠海联邦生物医药有限公司申报的司美格鲁肽注射液体重管理适应症获得中国国家药品监督管理局上市注册申请受理。司美格鲁肽注射液主要用于2型糖尿病患者的血糖控制、肥胖或超重患者的长期体重管理，并降低相关心血管不良事件风险。此次体重管理适应症的上市注册申报，进一步丰富了该产品的适应症布局，有望为更广泛的患者群体带来临床获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611053922758066.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611053922758066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B3M56506.USD","BK1191","IPOS","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786312","title":"【券商聚焦】中信建投：中国医药资产全球性价比凸显，内外协同空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786312?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:46","pubTimestamp":1793580413,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报称，2026年欧洲内科肿瘤学会 中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。该机构指，中国医药具有“创新升级+供应链韧性”优势，2025年创新药海外授权首付款大幅超去年全年，器械也在积极探索出海路径。美国主导早期研发与高端定价，但跨国药企专利悬崖下需求旺盛，中国资产全球性价比凸显，内外协同空间广阔。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","BK1610","BK0188","02196","LU0588546209.SGD","SG9999014674.SGD","BK1617","600056","IE00BPRC5H50.USD","BK1141","LU2476274720.SGD","01789","02268","LU0348767384.USD","03069","BK1161","LU2476274308.USD","LU0307460666.USD","LU0561508036.HKD","LU0417516902.SGD","LU0634319403.HKD","06160","KURE","02228","LU0348825331.USD","SG9999004311.SGD","IE00B5MMRT66.SGD","LU0228659784.USD","LU0348766576.USD","BK1588","LU0348783233.USD","LU1251922891.USD","02367","LU2399975544.HKD","601066","LU0348735423.USD","03933","LU1969619763.USD","09926","06821","01099","09688","KCE","LU0540923850.HKD","BK1515","BK0028","BK1207","LU1720050803.USD","BK1100","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677958931","title":"瑞银：降联邦制药(03933.HK)评级至“中性” 重申先声药业(02096.HK)为首选","url":"https://stock-news.laohu8.com/highlight/detail?id=2677958931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677958931?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:41","pubTimestamp":1792658506,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02096","03933","IE00B3M56506.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674823607","title":"东吴证券：维持联邦制药(03933)“买入”评级 主业筑底回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2674823607","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674823607?lang=zh_cn&edition=full","pubTime":"2026-10-12 11:12","pubTimestamp":1791774772,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东吴证券发布研报称，考虑到联邦制药为青霉素类抗生素产业链垂直一体化企业，中间体、原料药与兽药动保环节具备规模与成本优势，并已通过胰岛素类似物及UBT251等管线进入内分泌/代谢领域，该行看好公司未来主业周期修复与创新价值兑现形成共振，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601555","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674823602","title":"东吴证券：维持联邦制药(03933.HK)“买入”评级 主业筑底回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2674823602","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674823602?lang=zh_cn&edition=full","pubTime":"2026-10-12 11:12","pubTimestamp":1791774772,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","IE00B3M56506.USD","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157945476","title":"联邦制药9月无新增股份发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1157945476","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157945476?lang=zh_cn&edition=full","pubTime":"2026-10-05 10:41","pubTimestamp":1791168065,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司于2026年10月5日发布了截至2026年9月30日的证券变动月报表。根据公告，联邦制药普通股于当月未发生新增发行、购回或注销，报告期末已发行股份数为1,970,276,508股，库藏股为0股，合计已发行股份总数1,970,276,508股，与上月底持平。联邦制药确认已满足联交所规定的公共持股量要求，并持续遵守香港联交所《上市规则》及适用法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671576276","title":"港股异动 | 联邦制药(03933)涨超3% 德谷胰岛素利拉鲁肽注射液上市注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2671576276","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671576276?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:07","pubTimestamp":1790752022,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，联邦制药涨超3%，截至发稿，涨3.53%，报7.925港元，成交额2554.06万港元。　　消息面上，近日，联邦制药发布公告，公司全资附属公司珠海联邦生物医药有限公司自主研发的德谷胰岛素利拉鲁肽注射液获得中国国家药品监督管理局上市注册申请受理。公司为国内首家提交德谷胰岛素利拉鲁肽生物类似药上市注册申请的企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260930/32385297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03933","IPOS","KCAI","BK4585","VXUS","IE00B3M56506.USD","BK1191","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670352419","title":"智通港股早知道 | 监管明确险资投资港股通ETF口径 海光芯正(01191)南向持股占比升至4.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670352419","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670352419?lang=zh_cn&edition=full","pubTime":"2026-09-25 07:52","pubTimestamp":1790293960,"startTime":"0","endTime":"0","summary":"预计本公司将于2026年12月31日前与相关方订立合伙协议及附属协议。 海光芯正：下半年1.6T光模块开始出货 南向持股占比升至4.2%海光芯正在9月9日至11日举行的第27届中国国际光电博览会上，展出全栈自研硅光1.6T光模块和6.4T NPO。此外，南向资金近期持续加仓，海光芯正已于今年9月7日起纳入港股通。截至目前，南向资金持有海光芯正384.44万股，占公司已发行普通股的4.19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0140636845.USD","LU0871576103.HKD","VXUS","01133","LU2097828714.EUR","03692","LU1960683339.HKD","LU1226287875.USD","SG9999003461.SGD","IE00B543WZ88.USD","IE00B3M56506.USD","02628","LU1206782309.USD","03933","LU0320764599.SGD","IE00B5MMRT66.SGD","LU1152091754.HKD","BK4550","LU0315179316.USD","LU1008478684.HKD","01191","IE0032431581.USD","LU0307460666.USD","LU0326950275.SGD","00659","KCAI","KURE","BK1170","FLHK","LU0287142896.SGD","LU1226287529.USD","LU0708995583.HKD","BK1537","BK1205","FDN","LU1046422090.SGD","LU2097828631.EUR","BK1521","LU0067412154.USD","IE00B031HY20.USD","01093","LU0173614495.USD","BK1589","LU1152091168.USD","LU1226288170.HKD","LU1226287792.SGD","LU0211977185.USD","BK1230","BK1550","SG9999012710.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669491542","title":"联邦制药(03933)收取诺和关于UBT251独家许午可协议的第二次里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2669491542","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669491542?lang=zh_cn&edition=full","pubTime":"2026-09-24 23:01","pubTimestamp":1790262082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)发布公告，于2026年9月23日，联邦生物科技已收取诺和支付的UBT251注射液2型糖尿病适应症全球I期临床里程碑付款900万美元(扣除丹麦预缴税后)。根据独家许可协议并受其条款和条件约束，联邦生物科技有资格收取最高18亿美元的潜在里程碑付款，视乎达成若干开发和销售里程碑而定，以及可收取基于该地区的年度净销售额计算的分层销售提成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)收取诺和关于UBT251独家许午可协议的第二次里程碑付款","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3M56506.USD","BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171048187","title":"联邦制药（03933）获诺和诺德支付UBT251全球II期里程碑款900万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171048187","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171048187?lang=zh_cn&edition=full","pubTime":"2026-09-24 23:00","pubTimestamp":1790262047,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司（03933）9月24日公告称，其全资附属公司联邦生物科技已于2026年9月23日收到Novo Nordisk A/S（诺和诺德）就UBT251注射液治疗2型糖尿病适应症全球Ⅱ期临床试验达成的里程碑付款900万美元（税后）。\\n\\n该笔款项为双方于2025年3月24日签订之UBT251独家许可协议项下的第二次里程碑付款。根据该协议，联邦生物科技最多可获里程碑款合计18亿美元，并有权按相关地区年度净销售额收取分层销售提成。\\n\\nUBT251是一种同时靶向GLP-1受体、GIP受体及胰高血糖素受体的三重激动剂，用于治疗肥胖、2型糖尿病及其他相关疾病。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669495958","title":"联邦制药中期收入降18%，归母净利降81.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669495958","media":"财闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669495958?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:41","pubTimestamp":1790253660,"startTime":"0","endTime":"0","summary":"9月24日，联邦制药(03933.HK)公布截至2026年6月30日止六个月未经审计中期业绩，收入人民币61.66亿元，同比下降18.0%；本公司拥有人应占本期溢利人民币3.48亿元，同比下降81.6%。未计利息、税项、折旧及摊销前溢利为人民币9.21亿元，同比下降66.5%；除税前溢利为人民币4.65亿元，同比下降80.8%。每股基本盈利为人民币17.62分，同比下降83.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-24/doc-inisxtav8248894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03933","IE00B3M56506.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669246732","title":"联邦制药(03933)：德谷胰岛素利拉鲁肽注射液上市注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246732","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669246732?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:27","pubTimestamp":1790249237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，公司全资附属公司珠海联邦生物医药有限公司自主研发的德谷胰岛素利拉鲁肽注射液获得中国国家药品监督管理局上市注册申请受理，受理号为CXSS2600154。公司为国内首家提交德谷胰岛素利拉鲁肽生物类似药上市注册申请的企业。德谷胰岛素利拉鲁肽注射液是一款长效复方降糖制剂，由基础胰岛素德谷胰岛素和人胰高血糖素样肽-1类似物利拉鲁肽组成。本次上市注册申请是公司在糖尿病治疗领域又一重要成果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","IE00B3M56506.USD","BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110136157","title":"联邦制药（03933）德谷胰岛素利拉鲁肽注射液上市注册申请获中国药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1110136157","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110136157?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:25","pubTimestamp":1790249131,"startTime":"0","endTime":"0","summary":"2026年9月24日，联邦制药国际控股有限公司发布公告称，其全资子公司珠海联邦生物医药有限公司自主研发的德谷胰岛素利拉鲁肽注射液已获中国国家药品监督管理局受理上市注册申请，受理号为CXSS2600154。该公司成为国内首家提交该生物类似药上市注册申请的企业。\\n\\n德谷胰岛素利拉鲁肽注射液是一款长效复方降糖制剂，由基础胰岛素德谷胰岛素与GLP-1类似物利拉鲁肽组合而成。\\n\\n公司表示，此次注册申请是其在糖尿病治疗领域取得的又一重要进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667605723","title":"【券商聚焦】国联民生维持联邦制药（03933）推荐评级 指业绩环比改善显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2667605723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667605723?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:06","pubTimestamp":1789546009,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国联民生证券发布研报指，联邦制药 2026年上半年实现收入61.66亿元人民币（下同），同比下降18.0%；归母净利润3.48亿元，同比下降81.6%。报告称，许可收入上年同期基数高。随着中间体/原料药价格企稳复苏，公司整体业绩环比改善显著。投资建议方面，报告预计2026-2028年公司营业收入分别为124/132/143亿元人民币，同比增长-6.5%/6.9%/8.6%；归母净利润分别为7.6/10.3/11.7亿元人民币，同比增长-63.6%/35.4%/13.8%。当前股价对应PE分别为18X/13X/12X，维持“推荐”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991741","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","KCE","01456","601456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831355","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业(02096)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831355?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:43","pubTimestamp":1788939780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中国生物制药、石药集团及科伦药业，联邦制药表现大致符合预期，而三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","01530","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","03933","BK1583","03692","BK1589","BK1593","01477","02096","BK1574","HK0000165453.HKD","BK1191","IE00BZ08YT58.USD","BK1521","01177","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":-0.0591},{"period":"1month","weight":0.0225},{"period":"3month","weight":-0.1416},{"period":"6month","weight":-0.1705},{"period":"1year","weight":-0.4137},{"period":"ytd","weight":-0.3338}],"compareEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0278},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0896},{"period":"1year","weight":-0.1269},{"period":"ytd","weight":-0.0778}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联邦制药国际控股有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营业务。制剂产品分部主要制造及销售胰岛素系列产品、抗生素产品、眼科产品、兽药产品及空心胶囊等产品。原料药分部主要销售阿莫西林产品。中间体产品分部主要销售6-氨基青霉烷酸产品及青霉素G钾产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.033072},{"month":2,"riseRate":0.736842,"avgChangeRate":0.075941},{"month":3,"riseRate":0.631579,"avgChangeRate":0.024557},{"month":4,"riseRate":0.578947,"avgChangeRate":0.075619},{"month":5,"riseRate":0.631579,"avgChangeRate":0.035298},{"month":6,"riseRate":0.263158,"avgChangeRate":-0.013942},{"month":7,"riseRate":0.55,"avgChangeRate":0.015909},{"month":8,"riseRate":0.45,"avgChangeRate":0.020395},{"month":9,"riseRate":0.4,"avgChangeRate":-0.008264},{"month":10,"riseRate":0.6,"avgChangeRate":-0.008012},{"month":11,"riseRate":0.5,"avgChangeRate":-0.017268},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011203}],"exchange":"SEHK","name":"联邦制药","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联邦制药,03933,联邦制药股票,联邦制药股票老虎,联邦制药股票老虎国际,联邦制药行情,联邦制药股票行情,联邦制药股价,联邦制药股市,联邦制药股票价格,联邦制药股票交易,联邦制药股票购买,联邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}